Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK

• Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role
• Expanded senior team across clinical, CMC, regulatory and business development in the US and UK
• Global leader in developing a novel and highly differentiated payload class for ADCs, NMTi (N-myristoyltransferase inhibitors), to address the critical need to overcome payload resistance and improve tolerability

Parkinson’s UK Award Cellestial Health £55,000 to Continue Exploring Networks of Brain Cells That May Hold Answers for New Treatments for Parkinson’s

There are many different types of cells in the brain. We know that in Parkinson’s, brain cells that produce dopamine become damaged and start to die over time. However, it’s possible that other types of brain cells could also become damaged, and they may even play a role in why dopamine cells become unwell.

Taming the Untamable: Medicilon Powers KRAS-Targeted Therapies

KRAS is one of the most frequently mutated oncogenes in human cancers. Once thought “undruggable,” recent scientific advances have enabled the development of therapies targeting KRAS mutations, especially G12C, G12D, and G13D.

At Medicilon, we provide integrated preclinical services to support KRAS-targeted drug discovery and development:
✅ Drug discovery
✅ CMC research (API + formulation)
✅ Pharmacodynamics study
✅ Pharmacokinetics (PK) analysis
✅ Safety evaluation

Postdoctoral fellow - Saez-Rodriguez Group

The Saez-Rodriguez Research Group

The goal of the Saez Rodriguez group is to acquire a functional understanding of the deregulation of signalling networks in disease and to apply this knowledge to develop novel therapeutics. We focus on cancer, auto-immune and fibrotic disease. Towards this goal, we integrate big (‘Omics’) data with mechanistic molecular knowledge into statistical and machine learning methods, and we share our tools as free open-source packages.

Your Role

Ready-to-Use Sterile CAR-T Cell Lines for Leukemia Research.

Amsbio offers a growing list of experimental cell lines, recombinant proteins, and screening services to help accelerate the development of new CAR-T cell therapies. Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cell therapy for treatment of children and adolescents with B cell acute lymphoblastic leukemia (ALL).

Abzena Enhances AbZelectPRO™ Cell Line Offering with New GS Knockout Platforms

San Diego, CA – September 15, 2025 – Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its AbZelectPRO™ cell line development (CLD) platform with the launch of two next-generation Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins. The addition of the new GS knockout cell lines will further enhance speed, scalability, and flexibility for biopharma customers.

Coulter Partners places CSO at Alltrna

LONDON, UK and BOSTON, MA - September 18, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alltrna and is pleased to announce the placement of David (Dave) Hava, Ph.D., as Chief Scientific Officer (CSO).

Alltrna, a Flagship Pioneering company, is unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease.

Microbiotica Announces Completion of Recruitment in its International Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma | Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)

Cambridge, UK – 17 September 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its advanced melanoma (MELODY-1) trial.
This international trial has recruited 41 patients at clinical centres in the UK, France, Italy, and Spain. Initial results are expected in the first half of 2026.

Subscribe to